Equities, Investment & Market Trends
California Streamlines Medical Cannabis Licensing to Align with Federal Rescheduling and Tax Benefits
California's Department of Cannabis Control has streamlined medical cannabis licensing to align with federal rescheduling, enabling businesses to access c…
Australian Cannabis Policy & Law
US Lawful Hemp Protection Act Aims to Reshape Industrial Hemp Policy, Sparks Industry Debate
The proposed US Lawful Hemp Protection Act seeks to redefine industrial hemp policy by curbing synthetic intoxicants and clarifying CBD's legal status. Ex…
Equities, Investment & Market Trends
Moldova Expands Permitted Industrial Hemp Uses, Boosting Sector Value and Investment Potential
Moldova's government has significantly expanded permitted industrial hemp uses, including biomass and cosmetics, projecting a 40% value increase per hecta…
Equities, Investment & Market Trends
Class Action Lawsuit Alleges Cartel Manipulates Missouri Cannabis Market
A class action lawsuit alleges a 'cartel' led by Good Day Farm is manipulating the Missouri cannabis market, exceeding license caps and suppressing compet…
Equities, Investment & Market Trends
Safe Harbor Expands Medical Cannabis Financing Options for Industry Growth
Safe Harbor has expanded its medical cannabis financing platform, offering new lending capabilities for commercial real estate, working capital, and busin…
Moldova's new regulation significantly broadens the permitted uses for industrial hemp, allowing its application in fuel, cosmetics, and food additives. L…
Access & Prescribing (Australia & Global)
Federal Cannabis Rescheduling: DEA Registrations Open Amids…
Explore the latest developments in federal cannabis rescheduling, including the DEA's new registration process for medical cannabis businesses and ongoing…
Explore how Multi-State Operator TerrAscend is reportedly leading the cannabis industry forward, according to MJBizDaily. This analysis examines the signi…
Access & Prescribing (Australia & Global)
Medical Cannabis Product Claims Under Scrutiny by US Congre…
A U.S. congressional committee expresses concerns over unsubstantiated health claims for medical cannabis products, urging FDA enforcement. Learn about th…
Access & Prescribing (Australia & Global)
Trump Administration’s Partial Medical Cannabis Reschedulin…
Trump's partial medical cannabis rescheduling from Schedule I to III causes industry confusion. Learn its impact on medical products, regulatory pathways,…

